Citius Pharma Secures $5M to Fuel LYMPHIR Launch Amid Dilution Concerns

CRANFORD, NJ – April 24, 2026 – Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced today it has secured approximately $5 million in gross proceeds through a registered direct offering, a critical capital infusion aimed at funding the commercial rollout of its newly launched cancer therapy, LYMPHIR. The move, while essential for the company's growth, highlights the delicate balancing act that emerging biopharmaceutical firms must perform between financing ambitious goals and the potential dilution of existing shareholder value.

The financing comes just months after Citius Oncology, in which Citius Pharma holds a majority stake, launched LYMPHIR in December 2025. The immunotherapy is approved for adults with a specific form of Cutaneous T-Cell Lymphoma (CTCL). With a commercial product now on the market, the company faces the capital-intensive task of establishing a sales force, navigating reimbursement channels, and marketing the drug to physicians and patients—a challenge this new funding is designed to address directly.

The Anatomy of the Deal

In a move structured for speed and efficiency, Citius entered into a definitive agreement with institutional investors for the sale of common stock and warrants. The deal was priced "at-the-market" under Nasdaq rules, a mechanism that allows companies to sell securities at prevailing market prices.

The offering consisted of an aggregate of 5,076,143 units. A closer look at the SEC filings reveals a breakdown of 4,730,457 shares of common stock sold at $0.985 per share, alongside 345,686 pre-funded warrants sold at a slightly lower price of $0.9849 each. These pre-funded warrants function similarly to stock, being exercisable for a nominal fee ($0.0001 per share) at any time, a structure sometimes favored by institutional investors for ownership threshold reasons.

Concurrent with this public offering, Citius also conducted a private placement of unregistered warrants to purchase an additional 5,076,143 shares of common stock. These warrants carry an exercise price of $0.86 per share—notably below the offering's share price—and will be exercisable for five years once a registration statement for the underlying shares becomes effective. This warrant overhang represents a future source of potential capital for the company but also further potential dilution for its investors.

After accounting for fees paid to the exclusive placement agent, H.C. Wainwright & Co., and other offering expenses, Citius expects to receive net proceeds of approximately $4.5 million. As part of its compensation, H.C. Wainwright also received warrants to purchase 355,330 shares of common stock at an exercise price of $1.2313 per share.

A Balancing Act: Dilution vs. Growth

For current shareholders, the offering presents a classic biotech investment conundrum. The issuance of over 5 million new shares, with the potential for another 5 million from the private placement warrants, significantly increases the total number of outstanding shares. This dilution can put downward pressure on the stock price and reduces each existing share's claim on the company's future earnings.

The offering price of $0.985 was set against a closing price of $0.93 the day prior, indicating that the company was able to secure a price slightly above its recent market value. However, the inclusion of warrants with an exercise price of $0.86 provides an additional incentive to the new investors, a common feature in such financings for small-cap biotech companies that are often perceived as higher risk.

Investors must weigh this dilution against the strategic necessity of the funds. Without this capital, Citius's ability to effectively launch LYMPHIR and generate a sustainable revenue stream would be severely hampered. The $4.5 million in net proceeds provides a crucial runway to execute its commercial strategy. The market's reaction in the coming weeks will serve as a barometer of investor confidence, signaling whether they view the transaction as a necessary step toward unlocking future value or as an overly dilutive measure.

"It’s a trade-off that is front and center for any biotech that has a product on the cusp of commercialization," noted one anonymous industry analyst. "You have to spend money to make money, and in this sector, that initial spend is substantial. The question for investors is always whether management can deploy that capital effectively enough to generate a return that outweighs the dilution."

Beyond LYMPHIR: The Pipeline's Promise

The company has stated that the proceeds will not only support LYMPHIR but also advance its other development initiatives. This is a critical point for the company's long-term valuation, which rests on a pipeline of promising late-stage assets.

Chief among them is Mino-Lok, an antibiotic lock solution designed to salvage catheters in patients with catheter-related bloodstream infections (CRBSIs). This product candidate has already completed a pivotal Phase 3 trial where it successfully met both primary and secondary endpoints—a major clinical victory. Citius is currently engaged with the FDA to determine the next steps for a potential regulatory submission. A successful approval for Mino-Lok would address a significant unmet medical need and open up a substantial market.

Also in the late-stage pipeline is CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids that completed a Phase 2b trial in 2023. Like Mino-Lok, Citius is in discussions with the FDA regarding its development path forward. The capital from this offering provides the financial stability needed to continue these regulatory dialogues and prepare for potential future clinical or submission-related activities.

By allocating funds to these programs, Citius is signaling to investors that it is not a single-product company. The strategy is to build a multi-asset portfolio in the critical care space, mitigating risk and creating multiple shots on goal for long-term, sustainable growth.

A Common Play in the Biotech Field

While the specifics are unique to Citius, the financing strategy itself is a well-trodden path in the biopharmaceutical industry. Registered direct offerings, often paired with private placements of warrants, have become a go-to vehicle for small and mid-cap biotech companies to raise capital quickly and with more certainty than a traditional, lengthy public offering.

For companies transitioning from pure R&D to commercial operations—a period often referred to as the "valley of death" due to high cash burn and nascent revenues—access to capital markets is a lifeline. This type of financing allows management to seize opportunities and fund operations without the delay and market risk of a prolonged roadshow. It reflects the realities of a sector where scientific progress and commercial success are inextricably linked to financial liquidity. Citius's latest move is a pragmatic step to ensure it has the resources to turn its clinical achievements into commercial realities.